Zhao et al., 2017 - Google Patents
Graphene-based nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineeringZhao et al., 2017
View PDF- Document ID
- 12101967534730335964
- Author
- Zhao H
- Ding R
- Zhao X
- Li Y
- Qu L
- Pei H
- Yildirimer L
- Wu Z
- Zhang W
- Publication year
- Publication venue
- Drug Discovery Today
External Links
Snippet
Highlights•Graphene-based nanomaterials are emerging as the next generation's candidates for biotechnological advancements.•Graphene and its various derivatives have been covered.•The properties of graphene-based materials related to biomedical …
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [C] 0 title abstract description 368
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | Graphene-based nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineering | |
Bai et al. | Graphene: a versatile platform for nanotheranostics and tissue engineering | |
Dasari Shareena et al. | A review on graphene-based nanomaterials in biomedical applications and risks in environment and health | |
Zhao et al. | Temperature-sensitive lipid-coated carbon nanotubes for synergistic photothermal therapy and gene therapy | |
Zhao et al. | Synthesis of graphene quantum dots and their applications in drug delivery | |
Yadav et al. | 2D MoS2‐based nanomaterials for therapeutic, bioimaging, and biosensing applications | |
Zheng et al. | Polydopamine-coated magnetic composite particles with an enhanced photothermal effect | |
Mohajeri et al. | Biomedical applications of carbon nanomaterials: Drug and gene delivery potentials | |
Tonelli et al. | Graphene-based nanomaterials: biological and medical applications and toxicity | |
Shi et al. | Graphene-based magnetic plasmonic nanocomposite for dual bioimaging and photothermal therapy | |
Shen et al. | Biomedical applications of graphene | |
Dhas et al. | Molybdenum-based hetero-nanocomposites for cancer therapy, diagnosis and biosensing application: current advancement and future breakthroughs | |
Yang et al. | Stimuli responsive drug delivery systems based on nano-graphene for cancer therapy | |
Yang et al. | Nano-graphene in biomedicine: theranostic applications | |
Sontakke et al. | A comprehensive review on graphene oxide-based nanocarriers: Synthesis, functionalization and biomedical applications | |
Wu et al. | Current applications of graphene oxide in nanomedicine | |
Zhou et al. | Application of graphene/graphene oxide in biomedicine and biotechnology | |
Diez‐Pascual et al. | Functional nanomaterials in biomedicine: Current uses and potential applications | |
Zhang et al. | Graphene: a versatile nanoplatform for biomedical applications | |
Bai et al. | Multifunctional PEG-GO/CuS nanocomposites for near-infrared chemo-photothermal therapy | |
Lu et al. | Biodistribution of PEGylated graphene oxide nanoribbons and their application in cancer chemo-photothermal therapy | |
Krishna et al. | Graphene-based nanomaterials for nanobiotechnology and biomedical applications | |
Zuchowska et al. | Graphene as a new material in anticancer therapy-in vitro studies | |
Jaleel et al. | Reinforcing nanomedicine using graphene family nanomaterials | |
Liu et al. | NIR initiated and pH sensitive single-wall carbon nanotubes for doxorubicin intracellular delivery |